KRAS and colorectal carcinoma: The pharmacological rationale of the combination of FTD/TPI and bevacizumab was confirmed in preclinical models, and in particular on mice bearing SW48 (KRAS wild type) and HCT116 (KRAS mutated) human colorectal carcinoma xenografts.